Seres Therapeutics, Inc. (MCRB) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Seres Therapeutics is a commercial-stage microbiome therapeutics company. Its primary commercial asset is VOWST, the first FDA-approved orally administered microbiome therapeutic for preventing recurrent Clostridioides difficile infection (CDI), launched in June 2023 in collaboration with Nestlé Health Science. The company is also advancing SER-155, a live biotherapeutic candidate for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Material Transaction: On August 5, 2024 (post-period), Seres entered into an Asset Purchase Agreement to sell its VOWST business to a Nestlé subsidiary. The transaction is subject to stockholder approval and other conditions.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $0 |
| Net Loss | $(73,003) |
| Net Loss Per Share (Basic & Diluted) | $(0.49) |
| Operating Cash Flow | $(75,047) |
| Cash and Cash Equivalents (June 30, 2024) | $71,232 |
| Total Debt (Long-term Note Payable) | $102,494 |
| Accumulated Deficit | $(1,051,238) |
Note: Revenue was $0 for the period. In the prior year period, revenue was $125.95 million, driven by a milestone payment from Nestlé upon VOWST FDA approval.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped from $126.5 million in Q2 2023 to $0 in Q2 2024. The prior year included a $125 million milestone payment from Nestlé; no such milestone was achieved in the current period.
- Expense Reduction: Total operating expenses decreased significantly to $31.3 million in Q2 2024 from $76.9 million in Q2 2023. This reduction is primarily due to the restructuring plan implemented in late 2023 (41% workforce reduction) and the capitalization of manufacturing costs into inventory following VOWST's commercial launch.
- Collaboration Profit/Loss: The company recorded a collaboration profit of $2.6 million in Q2 2024 (vs. a loss of $2.1 million in Q2 2023). This shift is driven by a $9.2 million profit on the transfer of VOWST inventory to Nestlé, which offset the company's 50% share of the VOWST net operating loss ($6.6 million).
- Inventory Build: Inventories increased to $53.0 million from $29.6 million at year-end 2023, reflecting the capitalization of VOWST manufacturing costs.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for 12 months from the issuance date. This is due to the accumulated deficit and negative cash flows. The company's ability to continue operations depends on the successful closing of the Nestlé transaction or securing additional financing.
- Transaction Outlook: The pending sale of the VOWST business to Nestlé is expected to provide approximately $100 million in cash at closing (net of offsets), plus potential future milestones and installment payments. Proceeds are obligated to be used to fully retire the senior secured debt facility with Oaktree Capital Management.
- Debt Covenant Dispute: On May 1, 2024, the Oaktree agent issued a Notice of Default regarding a potential milestone payment to Bacthera (manufacturer). Seres disputes this, stating the payment is not yet due and does not constitute indebtedness under the credit agreement. The company intends to resolve this consensually or defend against acceleration.
- Restructuring: The company is on track to achieve estimated savings of $75–$85 million in 2024 from its restructuring plan.
- Pipeline: Post-transaction, the company plans to focus on SER-155. Enrollment for the Phase 1b Cohort 2 study is complete, with data readout anticipated in September 2024.
Investor Verification Checklist
- Transaction Closing: Verify the status of stockholder approval for the Asset Purchase Agreement with Nestlé, as this is the primary liquidity event.
- Debt Resolution: Monitor the resolution of the Oaktree Notice of Default and confirm the terms for the full repayment of the $110 million term loan upon transaction closing.
- Cash Runway: Assess the company's cash burn rate ($75 million used in operations for six months) against current cash balances ($71 million) to understand the timeline for additional funding needs if the transaction is delayed.
- Bacthera Milestone: Track the status of the Bacthera manufacturing suite "substantial completion" and the associated ~$28 million liability, which is a point of contention with the lender.
- SER-155 Data: Await the September 2024 data readout for the SER-155 Phase 1b study, which will be critical for the valuation of the remaining company post-transaction.